AMRN
Amarin Corporation plc
NASDAQ · Healthcare · Biotechnology · IE
$13.63
−0.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 186.2M | 213.6M | 228.6M | 306.9M | 369.2M |
| Cost of Revenue | 108.8M | 92.8M | 147.2M | 141.4M | 126.7M |
| Gross Profit | 77.4M | 120.9M | 81.4M | 165.5M | 242.5M |
| Operating Expenses | |||||
| R&D Expense | 18.3M | 19.8M | 20.9M | 22.2M | 30.4M |
| SG&A Expense | 83.1M | 115.0M | 152.3M | 199.9M | 304.4M |
| General & Admin Expense | 67.3M | 74.4M | 72.7M | 88.6M | 118.8M |
| Selling & Marketing Expense | 15.8M | 40.6M | 79.6M | 111.3M | 185.6M |
| Other Expenses | 9.4M | — | — | — | 13.5M |
| Total Operating Expenses | 110.7M | 134.8M | 173.2M | 222.2M | 348.4M |
| Cost and Expenses | 219.5M | 227.6M | 320.4M | 363.5M | 475.1M |
| Operating Income (EBIT) | (33.3M) | (13.9M) | (91.8M) | (56.6M) | (105.9M) |
| Non-Operating | |||||
| Interest Income | 10.8M | 10.9M | 13.4M | 11.9M | 2.8M |
| Interest Expense | — | 7.0K | 7.0K | 8.0K | 15.0K |
| Net Interest Income | 10.8M | 10.8M | 13.4M | 11.9M | 2.8M |
| Other Non-Op Income/Expense | 7.8M | (22.1M) | 14.6M | 2.9M | 2.1M |
| Non-Operating Income (excl Interest) | (10.8M) | 22.1M | (14.6M) | (3.0M) | (2.1M) |
| EBT (Pre-Tax Income) | (25.6M) | (36.0M) | (77.2M) | (53.7M) | (103.8M) |
| Income Tax Expense | 1.6M | 2.8M | 5.0M | 5.4M | 2.0M |
| Bottom Line | |||||
| Net Income | (27.1M) | (38.8M) | (82.2M) | (59.1M) | (105.8M) |
| Earnings from Cont. Ops | (27.1M) | (38.8M) | (82.2M) | (59.1M) | (105.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.1M) | (38.8M) | (82.2M) | (59.1M) | (105.8M) |
| Per Share | |||||
| Basic EPS | ($1.43) | ($1.80) | ($4.00) | ($3.00) | ($5.20) |
| Diluted EPS | ($1.43) | ($1.80) | ($4.00) | ($3.00) | ($5.20) |
| Revenue Per Share | $8.94 | $10.30 | $11.13 | $15.58 | $18.41 |
| Shares | |||||
| Basic Shares Outstanding | 20.8M | 20.7M | 20.5M | 19.7M | 20.1M |
| Diluted Shares Outstanding | 20.8M | 20.7M | 20.5M | 20.4M | 20.1M |
| Profitability Metrics | |||||
| EBITDA | (19.7M) | (33.0M) | (74.2M) | (50.7M) | (100.7M) |
| D&A | 2.8M | 3.0M | 3.0M | 3.0M | 3.1M |
| EBIT | (22.5M) | (36.0M) | (77.2M) | (53.7M) | (103.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026